Ignyta Company Profile (NASDAQ:RXDX)

About Ignyta (NASDAQ:RXDX)

Ignyta logoIgnyta, Inc. is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company's pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106. Entrectinib is an orally bioavailable, central nervous system (CNS)-active, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (TRK) family of tyrosine kinase receptors (TRKA, TRKB and TRKC), ROS1 and anaplastic lymphoma kinase (ALK) proteins. RXDX-105 is an orally bioavailable, vascular endothelial growth factor receptor (VEGFR)-sparing, small molecule tyrosine kinase inhibitor of rearranged during transfection (RET). Taladegib is an orally bioavailable, small molecule hedgehog/smoothened antagonist. RXDX-106 is a pseudo-irreversible, small molecule inhibitor of TYRO3, AXL and MER (collectively TAM), and c-MET.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RXDX
  • CUSIP: N/A
  • Web: www.ignyta.com
  • Market Cap: $598.66 million
  • Outstanding Shares: 41,836,000
Average Prices:
  • 50 Day Moving Avg: $7.49
  • 200 Day Moving Avg: $7.30
  • 52 Week Range: $4.15 - $10.60
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.32
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.39 per share
  • Price / Book: 7.30
  • EBIDTA: ($111,870,000.00)
  • Return on Equity: -113.19%
  • Return on Assets: -71.37%
  • Debt-to-Equity Ratio: 0.51%
  • Current Ratio: 5.14%
  • Quick Ratio: 5.14%
  • Average Volume: 705,498 shs.
  • Beta: 2.14
  • Short Ratio: 0.85

Frequently Asked Questions for Ignyta (NASDAQ:RXDX)

What is Ignyta's stock symbol?

Ignyta trades on the NASDAQ under the ticker symbol "RXDX."

How were Ignyta's earnings last quarter?

Ignyta, Inc. (NASDAQ:RXDX) announced its quarterly earnings results on Monday, May, 1st. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.69) by $0.27. View Ignyta's Earnings History.

Where is Ignyta's stock going? Where will Ignyta's stock price be in 2017?

4 analysts have issued 1-year target prices for Ignyta's shares. Their predictions range from $15.00 to $27.00. On average, they expect Ignyta's share price to reach $20.67 in the next year. View Analyst Ratings for Ignyta.

What are analysts saying about Ignyta stock?

Here are some recent quotes from research analysts about Ignyta stock:

  • 1. According to Zacks Investment Research, "Ignyta, Inc. is a biotechnology company. It develops precision medicine with integrated Rx/Dx solutions for cancer patients. The company focuses on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. Ignyta, Inc. is based in San Diego, California. " (5/30/2017)
  • 2. Cantor Fitzgerald analysts commented, "Entrectinib in ROS1 Shows Strong Interim Data. RXDX reported interim data in 32 patients with ROS1 NSCLC from the Phase II STARTRK2 trial, with an ORR of 75% (24/32 patients) as of a 12/16 cutoff, with a median duration of treatment of 17.2 months (PFS of 19.1 months, 63% of patients still on study). Looks Competitive. There are other agents for ROS1 NSCLC, but we think entrectinib is a competitive contender among the ROS1 agents. Of note are across-the-board positive ORR and DOR in both TKI-naive patients with and without CNS metastases: 34% of the patients in the dataset had CNS lesions, and responses were observed in 7/11, an ORR of 64%. NDA Strategy, Top Line Data in 2018. In addition to the data release RXDX confirmed the filing strategy that will see two separate NDAs for ROS1 NSCLC and a potential molecular defined label (rather than tumor-specific) label for TRK alterations. We anticipate the completion of enrollment of both ROS1 and TRK arms in 3Q17, with top line data in 1H18 and NDA filings in that year. Clear Strategy, Other Assets. With FDA confirmed regulatory plans in hand, we think the definitive NDA roadmap for entrectinib is a positive for the shares. We also believe that pipeline updates for RXDX-105, a BRAF/EGFR/RET inhibitor in Phase Ib, and RXDX-106, a Tyro-3/Axl/Mer (TAM) inhibitor in Phase I, could also be valuation drivers for the shares. Valuation and EPS. We have updated our model and are introducing our 2017 quarterly EPS forecasts." (4/28/2017)
  • 3. Jefferies Group LLC analysts commented, "ENA preclinical posters on RXDX-106 showed encouraging activity in both immuno-oncologic modulation and direct tumor targeting. These initial data support further development of ‘106 and we would look for more details at Dec 1 conference call. Incremental preclinical data of ‘105 and entrectinib were also presented." (11/30/2016)

Are investors shorting Ignyta?

Ignyta saw a increase in short interest in the month of June. As of June 15th, there was short interest totalling 2,207,239 shares, an increase of 167.4% from the May 31st total of 825,291 shares. Based on an average daily volume of 892,674 shares, the short-interest ratio is presently 2.5 days. Currently, 4.7% of the shares of the company are short sold.

Who are some of Ignyta's key competitors?

Who are Ignyta's key executives?

Ignyta's management team includes the folowing people:

  • Jonathan E. Lim M.D., Chairman of the Board, President, Chief Executive Officer, Co-Founder
  • Jacob M. Chacko M.D., Chief Financial Officer
  • Zachary Hornby, Chief Operating Officer
  • Valerie Harding Start Ph.D., Senior Vice President - Chemistry, Manufacturing, and Controls
  • Christian V. Kuhlen M.D. Esq., General Counsel, Secretary
  • William R. McCarthy, Chief Business Officer
  • Pratik S. Multani M.D., Chief Medical Officer
  • James A. Bristol Ph.D., Independent Director
  • Alexander W. Casdin, Independent Director
  • Heinrich Dreismann Ph.D., Independent Director

Who owns Ignyta stock?

Ignyta's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Tang Capital Management LLC (9.50%), Victory Capital Management Inc. (6.73%), Broadfin Capital LLC (6.30%), Vanguard Group Inc. (2.95%), RA Capital Management LLC (2.45%) and Frazier Management LLC (2.33%). Company insiders that own Ignyta stock include Alexander W Casdin, City Hill Venture Partners I,, Jacob Chacko, James A Bristol, James L Freddo and Jonathan E Lim. View Institutional Ownership Trends for Ignyta.

Who sold Ignyta stock? Who is selling Ignyta stock?

Ignyta's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Nationwide Fund Advisors, Bank of New York Mellon Corp and Morgan Stanley. View Insider Buying and Selling for Ignyta.

Who bought Ignyta stock? Who is buying Ignyta stock?

Ignyta's stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Victory Capital Management Inc., Broadfin Capital LLC, Nexthera Capital LP, EAM Investors LLC, Vanguard Group Inc., Neuberger Berman Group LLC and Citadel Advisors LLC. Company insiders that have bought Ignyta stock in the last two years include Alexander W Casdin, City Hill Venture Partners I,, Jacob Chacko, James A Bristol, James L Freddo and Jonathan E Lim. View Insider Buying and Selling for Ignyta.

How do I buy Ignyta stock?

Shares of Ignyta can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ignyta's stock price today?

One share of Ignyta stock can currently be purchased for approximately $10.15.

MarketBeat Community Rating for Ignyta (NASDAQ RXDX)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  180
MarketBeat's community ratings are surveys of what our community members think about Ignyta and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ignyta (NASDAQ:RXDX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.67 (103.61% upside)

Analysts' Ratings History for Ignyta (NASDAQ:RXDX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/22/2017Jefferies Group LLCReiterated RatingBuy -> Buy$27.00HighView Rating Details
6/4/2017Cantor FitzgeraldSet Price TargetBuy$15.00HighView Rating Details
8/10/2016Piper Jaffray CompaniesLower Price TargetOverweight$32.00 -> $20.00N/AView Rating Details
7/12/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
6/23/2016J P Morgan Chase & CoInitiated CoverageOverweight$15.00N/AView Rating Details
5/12/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 6/28/2015 forward)


Earnings History for Ignyta (NASDAQ:RXDX)
Earnings by Quarter for Ignyta (NASDAQ:RXDX)
Earnings History by Quarter for Ignyta (NASDAQ RXDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017Q1 2017($0.69)($0.96)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.67)($0.56)ViewN/AView Earnings Details
5/10/2016Q1($0.68)($0.79)ViewListenView Earnings Details
3/14/2016Q415($0.57)($1.32)ViewN/AView Earnings Details
11/9/2015Q315($0.60)($0.49)ViewN/AView Earnings Details
8/10/2015Q215($0.65)($0.51)ViewListenView Earnings Details
5/11/2015Q115($0.79)($1.15)ViewListenView Earnings Details
4/14/2015($0.79)($1.05)ViewN/AView Earnings Details
3/17/2015Q414($0.59)($2.18)ViewN/AView Earnings Details
11/7/2014Q314$0.01($0.55)$215.50 millionViewN/AView Earnings Details
8/12/2014($0.26)($0.28)$0.15 millionViewN/AView Earnings Details
5/12/2014($0.37)($0.28)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ignyta (NASDAQ:RXDX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.69)($0.69)($0.69)
Q3 20171($0.66)($0.66)($0.66)
Q4 20171($0.69)($0.69)($0.69)
(Data provided by Zacks Investment Research)


Dividend History for Ignyta (NASDAQ:RXDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ignyta (NASDAQ:RXDX)
Insider Ownership Percentage: 15.10%
Institutional Ownership Percentage: 47.79%
Insider Trades by Quarter for Ignyta (NASDAQ:RXDX)
Institutional Ownership by Quarter for Ignyta (NASDAQ:RXDX)
Insider Trades by Quarter for Ignyta (NASDAQ:RXDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2016James A BristolDirectorBuy5,000$5.65$28,250.00View SEC Filing  
5/4/2016Alexander W CasdinDirectorBuy232,000$6.25$1,450,000.00View SEC Filing  
3/17/2016Jacob ChackoCFOBuy10,000$5.64$56,400.00View SEC Filing  
3/17/2016James L FreddoDirectorBuy3,000$5.39$16,170.00View SEC Filing  
3/17/2016Jonathan E LimCEOBuy24,852$5.51$136,934.52View SEC Filing  
12/16/2015Jacob ChackoCFOBuy1,500$12.00$18,000.00View SEC Filing  
8/20/2015City Hill Venture Partners I,major shareholderBuy8,480$12.90$109,392.00View SEC Filing  
6/15/2015Robert WildVPBuy1,200$16.35$19,620.00View SEC Filing  
3/20/2015Jonathan E LimCEOBuy20,000$9.01$180,200.00View SEC Filing  
3/17/2015Alexander W CasdinDirectorBuy408,750$10.00$4,087,500.00View SEC Filing  
11/24/2014Jacob ChackoCFOBuy1,598$6.46$10,323.08View SEC Filing  
8/19/2014Jacob ChackoCFOBuy1,840$7.53$13,855.20View SEC Filing  
8/15/2014Jonathan E LimCEOBuy5,000$7.60$38,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Ignyta (NASDAQ:RXDX)
Latest Headlines for Ignyta (NASDAQ:RXDX)
americanbankingnews.com logoQ2 2017 Earnings Forecast for Ignyta, Inc. (RXDX) Issued By Jefferies Group
www.americanbankingnews.com - June 26 at 7:10 AM
americanbankingnews.com logoIgnyta, Inc. (RXDX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - June 23 at 10:38 PM
americanbankingnews.com logoIgnyta, Inc. (RXDX) to Post FY2021 Earnings of $2.02 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - June 23 at 1:26 PM
streetinsider.com logoUPDATE: Jefferies Assumes Ignyta, Inc (RXDX) at Buy - StreetInsider.com
www.streetinsider.com - June 23 at 9:44 AM
americanbankingnews.com logoIgnyta, Inc. (RXDX) Coverage Initiated by Analysts at Jefferies Group LLC
www.americanbankingnews.com - June 22 at 11:02 AM
americanbankingnews.com logoIgnyta, Inc. (RXDX) Expected to Post Earnings of -$0.52 Per Share
www.americanbankingnews.com - June 19 at 10:26 PM
americanbankingnews.com logoIgnyta, Inc. (RXDX) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - June 15 at 8:10 PM
americanbankingnews.com logoCantor Fitzgerald Reiterates $15.00 Price Target for Ignyta Inc (RXDX)
www.americanbankingnews.com - June 5 at 8:42 PM
finance.yahoo.com logoIgnyta to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 1 at 8:20 AM
americanbankingnews.com logoIgnyta Inc (RXDX) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - May 30 at 9:32 PM
americanbankingnews.com logoIgnyta Inc (RXDX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 29 at 8:50 PM
americanbankingnews.com logoIgnyta Inc (RXDX) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - May 27 at 8:16 PM
americanbankingnews.com logoIgnyta Inc (RXDX) Sees Large Increase in Short Interest
www.americanbankingnews.com - May 27 at 8:58 AM
streetinsider.com logoIgnyta (RXDX) Granted FDA Breakthrough Therapy Designation for Entrectinib
www.streetinsider.com - May 15 at 6:52 PM
americanbankingnews.com logoCantor Fitzgerald Analysts Give Ignyta Inc (RXDX) a $15.00 Price Target
www.americanbankingnews.com - May 15 at 3:14 PM
finance.yahoo.com logoIgnyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration
finance.yahoo.com - May 15 at 9:32 AM
americanbankingnews.com logoResearch Analysts Issue Forecasts for Ignyta Inc's FY2017 Earnings (RXDX)
www.americanbankingnews.com - May 11 at 10:52 AM
finance.yahoo.com logoIgnyta Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - May 9 at 7:09 PM
streetinsider.com logoIgnyta (RXDX) Prices 12.5M Common Stock Offering at $6.15/Share
www.streetinsider.com - May 4 at 8:58 AM
finance.yahoo.com logoIgnyta Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - May 4 at 8:57 AM
streetinsider.com logoIgnyta, Inc (RXDX) PT Lowered to $15 at Cantor Fitzgerald Following News of Equity Offering
www.streetinsider.com - May 4 at 12:20 AM
streetinsider.com logoIgnyta (RXDX) Plans 10M Share Offering of Common Stock
www.streetinsider.com - May 3 at 7:19 PM
finance.yahoo.com logoHere's Why Ignyta Dropped as Much as 19.9% Today
finance.yahoo.com - May 3 at 7:19 PM
americanbankingnews.com logoSomewhat Positive News Coverage Very Unlikely to Affect Ignyta (RXDX) Share Price
www.americanbankingnews.com - May 3 at 1:02 AM
finance.yahoo.com logoHere's Why Ignyta Shares Dropped as Much as 21.9% Today
finance.yahoo.com - May 2 at 5:28 PM
finance.yahoo.com logoIgnyta Announces Proposed Public Offering of Common Stock
finance.yahoo.com - May 2 at 5:28 PM
americanbankingnews.com logoIgnyta Inc (RXDX) Issues Earnings Results, Misses Estimates By $0.27 EPS
www.americanbankingnews.com - May 2 at 12:30 PM
americanbankingnews.com logoIgnyta Inc (RXDX) Expected to Announce Earnings of -$0.70 Per Share
www.americanbankingnews.com - May 1 at 7:44 PM
finance.yahoo.com logoIgnyta Announces First Quarter 2017 Company Highlights and Financial Results
finance.yahoo.com - May 1 at 6:55 PM
marketbeat.com logoIgnyta reports 1Q loss
marketbeat.com - May 1 at 6:04 PM
americanbankingnews.com logoIgnyta Inc (RXDX) Given "Buy" Rating at Cantor Fitzgerald
www.americanbankingnews.com - April 30 at 10:30 AM
americanbankingnews.com logoIgnyta (RXDX) Given Media Sentiment Rating of 0.33
www.americanbankingnews.com - April 29 at 8:29 PM
streetinsider.com logoAfter-Hours Stock Movers 04/27: (WDC) (GOOGL) (AMZN) Higher; (ATHN) (CLD) (SBUX) Lower (more...)
www.streetinsider.com - April 28 at 9:17 PM
finance.yahoo.com logoIgnyta Updates Progress towards Entrectinib Dual TRK and ROS1 NDA Submissions
finance.yahoo.com - April 27 at 8:05 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Somewhat Likely to Affect Ignyta (RXDX) Share Price
www.americanbankingnews.com - April 27 at 12:06 AM
finance.yahoo.com logoIgnyta to Host Conference Call and Webcast Update on Entrectinib Program and STARTRK-2 on April 27, 2017
finance.yahoo.com - April 24 at 6:06 PM
americanbankingnews.com logoIgnyta (RXDX) Receives Daily News Sentiment Rating of 0.28
www.americanbankingnews.com - April 22 at 3:34 PM
americanbankingnews.com logoPositive Media Coverage Somewhat Likely to Impact Ignyta (RXDX) Stock Price
www.americanbankingnews.com - April 19 at 11:17 AM
americanbankingnews.com logoSomewhat Positive Media Coverage Unlikely to Effect Ignyta (RXDX) Share Price
www.americanbankingnews.com - April 14 at 10:23 PM
finance.yahoo.com logoIgnyta Announces New Data Highlighting Broad Potential of Both RXDX-106 and Entrectinib at the 2017 AACR Annual Meeting
finance.yahoo.com - April 7 at 12:25 PM
americanbankingnews.com logoIgnyta Inc (RXDX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 5 at 4:57 PM
us.rd.yahoo.com logoIgnyta Announces Peer-Reviewed Publication of Activity of a TRK Inhibitor in a Primary Brain Tumor: Successful Treatment of Glioneuronal Tumor With Pan-TRK, CNS-Active Inhibitor Entrectinib Published in Precision Oncology
us.rd.yahoo.com - March 30 at 7:53 PM
streetinsider.com logoIgnyta (RXDX) Announces Multiple Presentations at AACR
www.streetinsider.com - March 29 at 12:32 AM
us.rd.yahoo.com logoIgnyta Announces Multiple Presentations at the 2017 AACR Annual Meeting
us.rd.yahoo.com - March 28 at 7:31 PM
americanbankingnews.com logoIgnyta Inc (RXDX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 25 at 7:23 AM
streetinsider.com logoPre-Open Movers 03/24: (HTGM) (SEAS) (MU) Higher; (XENE) (FINL) (GME) Lower (more...)
www.streetinsider.com - March 24 at 7:27 PM
finance.yahoo.com logo4:00 pm Ignyta is exploring strategic options for taladegib and has entered into an amended and restated license, development and commercialization agreement with Eli Lilly (LLY) for the taladegib oncology
finance.yahoo.com - March 23 at 8:07 PM
finance.yahoo.com logoIgnyta Announces Exploration of Strategic Options for Taladegib, Enabled by Amendment of Taladegib License Agreement with Lilly
finance.yahoo.com - March 23 at 8:07 PM
biz.yahoo.com logoIGNYTA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - March 23 at 8:07 PM
finance.yahoo.com logoIGNYTA, INC. Financials
finance.yahoo.com - March 18 at 6:52 PM



Ignyta (RXDX) Chart for Wednesday, June, 28, 2017

This page was last updated on 6/28/2017 by MarketBeat.com Staff